close icon

Nvidia Stock to Take a Turn for the Worse?

Nvidia shareholders have plenty to be grateful for so far in 2019. The stock is up nearly 37% since we wrote about it in January. On the third day of the new year NVDA was hovering around $136 a share following a sharp selloff from ~$293.

However, the five-wave impulse pattern formed by this plunge indicated that Nvidia was ready for a recovery towards $180-$190. The stock reached that area in April and is once again trading within its boundaries now. The time seems right to take another look and see what to expect going forward.

Nvidia stock completes bearish Elliott Wave cycle

The 4-hour chart reveals the impulsive crash from $293 to $125 as well as the following recovery. Wave (2/B) appears to be an a-b-c flat correction, whose wave “c” is an ending diagonal. According to the Elliott Wave theory, more weakness in wave (3/C) can be expected as soon as wave (2/B) ends.

Furthermore, wave (3/C) is supposed to breach the bottom of wave (1/A). This means targets below $124 a share are plausible, once the downtrend resumes. If this analysis is correct, NVDA can lose more than a third of its market value in the months ahead. Given the company’s cyclical nature and the numerous recession indicators flashing red, this is a warning the bulls cannot afford to ignore.

Did you like this analysis? Similar Elliott Wave setups occur in the Forex, crypto and commodity markets, as well. Our Elliott Wave Video Course can teach you how to uncover them yourself!



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Bristol-Myers Stock Pattern Triggers a 37% Surge

Bristol-Myers Squibb and Celgene are expected to merge into a single company before the end of the year. The deal will create the fifth largest pharmaceutical company in the world with sales of approximately $42 billion in 2019. Bristol-Myers fell sharply after the deal was announced in early-January. In late-April, the stock was still in…

Read More »

Home Capital: Third Wave Lifts Stock 140% in 2019

Home Capital Group is up 17.4% in Toronto today following the company’s third quarter financial report. The mortgage lender beat analysts’ earnings expectations and delivered improvements in other areas, too. In total, HCG is up ~140% in 2019. But things didn’t look so rosy at the beginning of the year. The stock was hovering in…

Read More »

Walgreens: Did the Market Foresee that KKR Offer?

Anyone who’s been in Elliott Wave analysis long enough has noticed how often some external factor “makes the price move” in the direction the analysis had identified much earlier. We’ve seen it happening in crypto, we’ve seen in happening in stock indices. Now, it happened with Walgreens stock. Walgreens jumped on November 5th after CNBC…

Read More »

SERV Stock Gave a Warning Before Crashing 40%

The last three weeks have been tough on ServiceMaster shareholders. SERV stock was hovering around $56 a share as October went into its final third. But when the company announced its preliminary Q3 results on October 22nd, all hell broke loose. Apparently, Wall Street didn’t like what it saw, which resulted in a swift and…

Read More »

Expedia Disappointed. Elliott Wave Analysis Did Not

Expedia stock is down 25% today after the company’s Q3 results missed expectations. GAAP EPS fell 57 cents short of analysts’ estimates. The revenue figure was anticipated to be $10 million higher than reported, as well. On top of that, Expedia cut its full-year guidance which annoyed Wall Street even more. That is the official…

Read More »

SEIC Stock Can Lose Half its Value in a Recession

SEI Investments provides investment management, processing and platforms for private banks, institutional investors and investment advisors and managers. With a market cap of roughly $9.4 billion, the company is in the mid-cap category, which is generally thought to offer some of the best growth potential opportunities. But is SEIC stock a good choice around $62…

Read More »

DexCom ‘s Wall Street Darling Status is in Danger

In previous articles, we’ve discussed numerous stocks, which brought their investors great returns in the past decade. Today’s material will focus on one that beats them all. DexCom – a medical device company, headquartered in San Diego, California. In November 2008, during the throes of the Financial Crisis, DXCM stock plunged to as low as…

Read More »

More analyses